Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of low-density lipoprotein particle receptors. [GOC:mah]
Positive regulation of low-density lipoprotein particle receptor catabolic process is a complex biological process that involves the regulation of the breakdown and removal of low-density lipoprotein (LDL) receptors from the cell surface. LDL receptors play a crucial role in the uptake of LDL, a type of cholesterol-carrying particle, from the bloodstream. The catabolism of LDL receptors is tightly controlled to maintain appropriate levels of cholesterol within cells. This process is essential for preventing the accumulation of LDL in the blood, which can contribute to the development of atherosclerosis and cardiovascular disease.
The positive regulation of LDL receptor catabolism involves a series of molecular events that promote the degradation of these receptors. These events include:
1. **Ligand binding:** LDL particles bind to LDL receptors on the cell surface, initiating the endocytosis of the receptor-ligand complex.
2. **Internalization:** The LDL receptor-ligand complex is internalized into the cell via endocytosis, forming a vesicle called an endosome.
3. **Sorting and trafficking:** Within the endosome, LDL receptors are sorted away from LDL particles. LDL is destined for lysosomal degradation, while LDL receptors are recycled back to the cell surface.
4. **Recycling:** LDL receptors are transported from endosomes back to the cell surface via a process called recycling. This ensures that LDL receptors are available for further rounds of LDL uptake.
5. **Degradation:** A portion of LDL receptors undergo degradation within lysosomes. This degradation pathway helps to regulate the overall number of LDL receptors on the cell surface.
Several factors can influence the positive regulation of LDL receptor catabolic process, including:
* **Cholesterol levels:** High levels of intracellular cholesterol can suppress the synthesis of LDL receptors, reducing LDL uptake and promoting receptor degradation.
* **Hormones:** Hormones like insulin and thyroid hormones can influence LDL receptor expression and activity, affecting LDL uptake and catabolism.
* **Genetic factors:** Variations in genes involved in LDL receptor metabolism can influence individual susceptibility to hypercholesterolemia and cardiovascular disease.
Understanding the mechanisms of positive regulation of LDL receptor catabolic process is crucial for developing therapeutic strategies to reduce LDL levels and prevent cardiovascular disease. By targeting key components of this process, it may be possible to enhance LDL receptor expression, promote receptor recycling, and reduce receptor degradation, leading to improved cholesterol management and cardiovascular health.'
"
Protein | Definition | Taxonomy |
---|---|---|
Proprotein convertase subtilisin/kexin type 9 | A proprotein convertase subtilisin/kexin type 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8NBP7] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
s 1033 | (trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide | anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor | |
PF-06446846 | PF-06446846 : A triazolopyridine that is 3H-[1,2,3]triazolo[4,5-b]pyridine substituted by a 4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}phenyl group at position 3. It is a potent inhibitor of PCSK9. PF-06446846: inhibits translation of PCSK9 ;structure in first source | benzamides; monochloropyridine; piperidines; tertiary carboxamide; triazolopyridine | antilipemic drug; EC 3.4.21.61 (kexin) inhibitor |